Insulet Corp
NASDAQ:PODD
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
237.06
352.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Insulet Corp
NASDAQ:PODD
|
20B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
210.8B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
186.6B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
136.3B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
128B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
58.7B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
48.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55.7B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
49.3B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.6B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Insulet Corp
Glance View
Insulet Corporation has carved out a significant niche in the medical device industry, distinguishing itself through its innovative approach to diabetes management. The company is best known for its Omnipod Insulin Management System, a discreet, tubeless insulin pump that provides a solution for individuals with diabetes seeking an alternative to traditional insulin delivery methods. Unlike conventional pumps that require cumbersome tubes and significant patient involvement, the Omnipod system offers ease and convenience, allowing users more freedom and flexibility in their daily lives. The system operates via a small wearable pod that delivers insulin over several days, which users control remotely, removing much of the hassle associated with managing diabetes. Insulet generates revenue by selling these pods and the associated Personal Diabetes Manager (PDM) devices, which together comprise the entire system. Customers typically purchase pods on a recurring basis, similar to a subscription model, which creates a steady stream of revenue for the company. The business model emphasizes continuous growth by expanding its user base and improving its technology to remain at the forefront of patient-centric diabetes care. Insulet's strategic focus on the needs of its users and commitment to refining their health technology has enabled it to build a sustainable business that addresses a critical healthcare challenge while also delivering consistent financial performance.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Insulet Corp is 9.8%, which is below its 3-year median of 11.5%.
Over the last 3 years, Insulet Corp’s Net Margin has increased from 1.4% to 9.8%. During this period, it reached a low of 0% on Mar 31, 2023 and a high of 21.2% on Sep 30, 2024.